Details of the Drug

General Information of Drug (ID: DMCDUJY)

Drug Name
Anti-CD20-CAR vector-transduced autologous T cells
Indication
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Phase 1/2 [1]
B-cell chronic lymphocytic leukaemia 2A82.00 Phase 1/2 [1]
Diffuse large B-cell lymphoma 2A81 Phase 1/2 [1]
Follicular lymphoma 2A80 Phase 1/2 [1]
Haematopoietic/lymphoid cancer 2B33.5 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Prolymphocytic leukaemia 2A82.1 Phase 1/2 [1]
⏷ Show the Full List of Indication(s)
Drug Type
CAR T Cell Therapy
Cross-matching ID
TTD ID
D0V6VD
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN CAR-T-Cell-Therapy [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy